New Article Discusses Treatment Options for Weight Management in People With
Type 2 Diabetes
MOUNTAIN VIEW, Calif., June 7, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc.
(Nasdaq:VVUS) today announced that a review article has been published online
in The Journal of Diabetes and Its Complications examining the importance of
weight management in the treatment of type 2 diabetes. The article reviews
treatment options, including lifestyle interventions, pharmacotherapy and
surgery, citing Qsymia^® (phentermine and topiramate extended-release)
capsules CIV as a treatment option.
Authors: Robert R. Henry, Robert Chilton, W. Timothy Garvey
Title: "New options for the treatment of obesity and type 2 diabetes
According to the article, studies have shown that moderate weight loss in
obese patients with type 2 diabetes mellitus (T2DM) can lead to reductions in
cardiometabolic risk factors such as dyslipidemia and hypertension and can
have a substantial impact on mortality.
Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet
and increased physical activity for chronic weight management in adults with
an initial body mass index (BMI) of 30 kg/m^2 or greater (obese) or 27 kg/m^2
or greater (overweight) in the presence of at least one weight-related medical
condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.
Important Safety Information
Qsymia (phentermine and topiramate extended-release) capsules CIV is
contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism;
in patients receiving treatment or within 14 days following treatment with
monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive ingredients in
Qsymia can cause fetal harm. Females of reproductive potential should have a
negative pregnancy test before treatment and monthly thereafter and use
effective contraception consistently during Qsymia therapy. If a patient
becomes pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential hazard to the
The most commonly observed side effects in controlled clinical studies, 5% or
greater and at least 1.5 times placebo, include paraesthesia, dizziness,
dysgeusia, insomnia, constipation, and dry mouth.
VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health. For more information about the company,
please visit www.vivus.com.
Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. VIVUS does
not undertake an obligation to update or revise any forward-looking
statements. Investors should read the risk factors set forth in VIVUS's Form
10-K for the year ending December 31, 2012, as amended by the Form 10-K/A
filed on April 30, 2013, and periodic reports filed with the Securities and
CONTACT: VIVUS, Inc.
Dana B. Shinbaum
The Trout Group
Joele Frank, Wilkinson Brimmer Katcher
Matthew Sherman | Jennifer Beugelmans
email@example.com | firstname.lastname@example.org
212-235-2665 | 212-895-8692
Press spacebar to pause and continue. Press esc to stop.